Axon Enterprise Faces Massive Insider Selling as Stock Slides 32% YTD
In the past twelve months Axon Enterprise insiders have sold $124 million of stock while buying just $1 million, driving the buy‑sell ratio down to 0.01x. The bulk of the disposals came from the CEO, CFO and other C‑suite executives, a pattern that stands out against a backdrop of a 32% year‑to‑date price decline.
Axon Enterprise’s insider activity over the last year is dominated by selling. Insiders executed 211 sell transactions totaling $124,012,531, contrasted with a single purchase of $1,004,920 by a director in August 2025. The resulting buy‑sell ratio of 0.01x falls well below the 0.2x threshold that flags heavy insider selling, suggesting a level of disposition that exceeds routine compensation or diversification moves.
The CEO, Patrick W. Smith, alone accounted for $51,111,184 in sales, the largest single‑person total, including a $5,002,400 sale of 10,000 shares on February 25, 2026. The CFO contributed $9,285,793 across 15 transactions, while the broader C‑suite (excluding the CEO and CFO) sold $57,744,963 in 70 deals. Combined, the three senior‑level groups disposed of $108,141,940, or roughly 87% of all insider‑reported value changes. Such concentration among top executives is a stronger signal than director‑level trades, which together amounted to just $5,870,591.
Monthly activity highlights several spikes. August 2024 recorded $82,764,181 in sales, the highest single‑month total, followed by September’s $59,354,523 and October’s $66,807,442. These three months alone represent more than half of the year‑to‑date sell volume, indicating clustered selling that aligns with the “cluster selling” pattern often interpreted as a lack of confidence in near‑term prospects. Additional notable months include December 2025 ($21,059,196) and March 2026 ($28,168,601), each reflecting multi‑million disposals by the same C‑suite insider, Joshua Isner, who alone generated over $13 million in sales across three separate transactions in March 2026.
The market context amplifies the significance of this activity. Axon’s share price sits at $386, down 0.98% on the day and trailing 32% YTD, positioning the stock at the low‑9% point of its 52‑week range. The Relative Strength Index of 48 suggests the stock is neither oversold nor overbought, leaving the price largely driven by fundamentals and sentiment rather than technical extremes. A market‑cap of $31.1 billion underscores the company’s size, meaning insider sales of this magnitude represent a material reallocation of wealth.
While insider selling can stem from pre‑arranged trading plans, the sheer volume, the dominance of C‑suite participants, and the timing of clustered disposals raise questions about internal confidence. Investors should monitor whether the selling persists, whether any new insider purchases emerge, and how the company’s operational performance evolves amid a challenging stock trajectory.
Monthly Insider Activity
Activity by Role
Financial Details
| Buy Count | 1 |
| Sell Count | 211 |
| Buy Value | 1,004,919.73 |
| Sell Value | 124,012,531.11 |
| Total Value | 125,017,450.84 |
| Buy Sell Ratio | 0.01 |
| C Suite Activity | Yes |
Key Takeaways
- Insider sell value $124.0 M vs buy value $1.0 M; buy‑sell ratio 0.01x.
- CEO, CFO and other C‑suite sold a combined $108.1 M, representing 87% of total insider transaction value.
- No insider buying in 12 months except a single $1.0 M director purchase in August 2025.
- Stock down 32% YTD, trading at 9% of its 52‑week range; RSI 48 indicates neutral momentum.